AstraZeneca is considering moving its stock market listing from London, where it is the exchange's most valuable company, to ...

AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as ...

The company's exit from the U.K. market would spark a major index re-weighting, given AstraZeneca is the most valuable ...

Despite a Q1 revenue miss due to currency headwinds, core EPS beat expectations for AstraZeneca. Read why AZN stock is a Buy.

Summit Therapeutics and AstraZeneca are discussing a partnership deal worth as much as $15 billion, Bloomberg News reported ...

AstraZeneca (LSE:AZN) received EU approval for its cancer treatment Imfinzi, marking a significant product-related milestone.

(Reuters) -AstraZeneca CEO Pascal Soriot is considering moving the company's stock market listing to the U.S., the Times ...

AstraZeneca PLC closed 23.68% short of its 52-week high of £133.88, which the company achieved on September 3rd.

Summit Therapeutics jumps 9% as AZN eyes a potential $15 billion licensing deal for its cancer drug, ivonescimab.

Months after announcing an M&A deal with AstraZeneca, EsoBiotec has released the first small slice of data on the cell ...

AstraZeneca outperforms markets YTD amid eased concerns, China clarity, minimal US tariff impact, and attractive valuations.

AstraZeneca Plc’s shares rose after a report that Chief Executive Officer Pascal Soriot wants to move the British drugmaker’s ...